Zhongnan Medical Journal Press

Home Results

A total of 5 result was found. Results that relate to Mutation

Familial amyotrophic lateral sclerosis: a report of two cases

Published on New Medicine 2022,32(1):229-232.
12846 times 3991 times

Zeng LI Jun-Jian ZHANG

Familial amyotrophic lateral sclerosis SOD1 G147D Gly148Asp Genes Mutation
Details
Treatment of a patient with EGFR L747S and L858R double-mutated lung adenocarinoma

Published on Journal of Mathematical Medicine 2023,36(3):230-235.
7325 times 2122 times

Teng-Fei WANG Wen OUYANG Jun-Hong ZHANG Gong ZHANG Cong-Hua XIE

EGFR L747S mutation Lung adenocarcinoma Osimertinib Pem-brolizumab
Details
The correlation between MTHFD2 and the tumor microenvironment in head and neck squamous cell carcinoma

Published on New Medicine 2024,34(3):291-300.
10900 times 3020 times

SHI Zhenxiang WU Sa CAI Weisong MING Xiaoping CHEN Xiong

MTHFD2 Head and neck squamous cell carcinoma Prognosis Tumor mutation burden
Details
Influencing factors of the therapeutic effect of PD-1 inhibitor pembrolizumab on cervical cancer

Published on Frontiers in Pharmaceutical Sciences 2024,27(8):1375-1382.
9327 times 1883 times

HU Jinghua SANG Xuemei QIAO Wei ZHANG Miao

Programmed death-1 Programmed death-ligand 1 Pabolizumab Cervical carcinoma Tumor mutation burden Tumor infiltrating lymphocytes Neoantigen intra-tumoral heterogeneity
Details
Cost-effectiveness analysis of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment for progressed EGFR-mutant non-small-cell lung cancer

Published on Chinese Journal of Pharmacoepidemiology 2026,35(5):553-562.
1443 times 273 times

JIN Lijun ZHANG Lele HAN Lu LYU Zhenye

Sacituzumab tirumotecan Non-small cell lung cancer EGFR mutation Quality adiusted life year Incremental Cost-effectiveness ratio Cost-effectiveness analysis Scenaio analysis
Details